Global Cell Therapy Market & Pipleine Insight
Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stem become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice.
Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body’s own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.
The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.
With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases.
“Global Cell Therapy Market & Pipeline Insight” Report Highlights & Findings:
- Introduction to Cell therapy
- Global Cell Therapy Market Overview
- Global Cell Therapy Market Dynamics
- Cell Therapy Pipeline by Phase, Country & Target Indications
- Cell Therapy Drugs in Pipeline: More Than 200
- Highest Number of Drugs in Preclinical Stage: 73
- Number of Drugs in Phase I/II Stage: 35
- Key Market: US
- Majority Cell therapies For Cancer Treatment
1.1 Origin of Cell Therapy
1.2 The Process of Cell Therapy
2. GLOBAL CELL THERAPY MARKET OVERVIEW
2.1 Cell Therapy Market by Segments
2.2 Cell Therapy Market by Indications
2.3 Regional Market Analysis
2.4 Market Trends
2.5 Cell Therapy Pipeline
3. GLOBAL CELL THERAPY MARKET DYNAMICS
3.1 Favorable Market Drivers
3.2 Challenges to be Resolved
3.3 Future Growth Opportunity
4. CELL THERAPY KEY DEVELOPMENTS
4.1 Shift from Autologous to Allogeneic Cell Therapies
4.2 Cell Collection Challenges to be Overcome
4.3 Reducing Manufacturing Risk
5. CELL THERAPY PIPELINE BY PHASE, COUNTRY & TARGET INDICATIONS
5.1 Research till Registration
5.2 Marketed Cell Therapy Drugs
5.3 Discontinued & Suspended
6. PANCREATIC BETA CELL REPLACEMENTS THERAPY PIPELINE BY PHASE, COUNTRY & TARGET INDICATIONS
6.1 Research till Registration
6.2 Discontinued & Suspended
7. DOPAMINERGIC CELL REPLACEMENTS THERAPY PIPELINE BY PHASE, COUNTRY & TARGET INDICATIONS
7.1 Research till Registration
7.2 Discontinued & Suspended
8. COMPETITIVE LANDSCAPE
8.1 Amgen
8.2 Advanced Cell Technology
8.3 Celgene Corporation
8.4 Cytomedix
8.5 California Stem Cell
8.6 Fibrocell Science
8.7 Genzyme
8.8 NeoStem
8.9 Novartis
8.10 Stemedica Cell Technologies
Figure 1-1: The Four Pillars of Global Pharmaceutical Industry
Figure 1-2: Composition of Cell Therapy
Figure 2-1: Global Cell Therapy Market (US$ Billion), 2012-2018
Figure 2-2: Global Cell Therapy Market by Indications, 2013
Figure 2-3: Global Cell Therapy Market by Region (%), 2013 & 2018
Figure 2-4: Global Cell Therapy Drug Pipeline by Phase(%), 2014
Figure 2-5: Global Cell Therapy Drug Pipeline by Phase (Number of Drugs), 2014
Figure 2-6: Pancreatic Beta Cell Replacement Therapy Pipeline by Phase (%), 2014
Figure 2-7: Pancreatic Beta Cell Replacement Therapy Pipeline by Phase (Number of Drugs, 2014
Figure 2-8: Dopaminergic Cell Replacement Therapy Pipeline by Phase (%), 2014
Figure 2-9: Dopaminergic Cell Replacement Therapy Pipeline by Phase (Number of Drugs), 2014
The cell therapy market offers wide market potential and a favorable landscape for adoption across many geographical locations of the world. With a major part of the industry-sponsored clinical trials concentrated in the USA, this region accounts for the major share in the global pie followed by Europe and Asia-Pacific regions. As the USA accounts for a dominant share of more than xx% in the global cell therapy market, there are more than 15 cell therapy products commercially distributed by companies in the USA. These include Dermagraft, Osteocel, PureGen, BioDfactor, BioDfence, Provenge, Carticel, Epicel, Nucel, Appligraf, GINTUIT, Trinity, Grafix, DeNovoET, Prokera, and AmnioGraft. Though during the period xxx, no cell therapy products received regulatory approval, in the past few years, the market in USA has grown with xx such approvals in quick succession.
The cell therapy market offers wide market potential and a favorable landscape for adoption across many geographical locations of the world. With a major part of the industry-sponsored clinical trials concentrated in the USA, this region accounts for the major share in the global pie followed by Europe and Asia-Pacific regions. As the USA accounts for a dominant share of more than xx% in the global cell therapy market, there are more than 15 cell therapy products commercially distributed by companies in the USA. These include Dermagraft, Osteocel, PureGen, BioDfactor, BioDfence,
Provenge, Carticel, Epicel, Nucel, Appligraf, GINTUIT, Trinity, Grafix, DeNovoET, Prokera, and AmnioGraft. Though during the period xxx, no cell therapy products received regulatory approval, in the past few years, the market in USA has grown with xx such approvals in quick succession.
With a major section of the clinical trials conducted in the Asia-Pacific region focusing on indications like cancer, musculoskeletal diseases, non-healing wounds, and cardiac diseases, the region offers a strong pipeline of cell therapies in the future.
Additionally, the region is an attractive destination for contract manufacturing activities owing to advantages like low costs of manufacturing, abundant labor etc.
Since the global cell therapy market is shifting towards a more outsourced model, with CMOs(Contract Manufacturing Organizations) playing a significant role, Asia offers huge market potential for the pharma companies investing in the cell therapy market.
